Sabag Mark 4

What Happened
Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries Ltd., reported the sale of 144,180 ordinary shares (which may be represented by American Depositary Shares, 1 ADS = 1 ordinary share). The shares were sold in multiple open‑market transactions on May 1, 2026 at a weighted average price of $34.99, generating approximately $5,045,118 in proceeds. This was a sale (disposition), not a purchase.

Key Details

• Transaction date: May 1, 2026 (reported on Form 4 filed May 4, 2026).
• Price: Weighted average $34.99; sale prices ranged from $34.935 to $35.07 (report notes multiple transactions).
• Shares sold: 144,180; Total proceeds: ~$5,045,118.
• Shares owned after transaction: Not specified in this filing.
• Footnotes of note:
  • F1: Ordinary shares may be represented by ADSs (1 ADS currently = 1 Ordinary Share).
  • F2: Weighted average price reported; reporting person will provide, upon request, the number of shares sold at each separate price.
• Timeliness: Filing date provided; the Form 4 reports the May 1 transaction and does not indicate a late filing.

Context

• This filing records a sale, which is a routine insider disposition and should not be interpreted as evidence of company performance without additional context.
• The sale was executed in multiple open‑market transactions (not an option exercise or gift).